Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan

M Namba, Y Kaneda, M Iida - Therapeutic Advances in …, 2023 - journals.sagepub.com
TherapeuTic advances in vaccines and immunotherapy population across 47 countries
includes male vaccination within their routine immunization programs. 5 The HPV vaccine …

[引用][C] Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan.

M Namba, Y Kaneda, M Iida - Therapeutic Advances in Vaccines …, 2023 - europepmc.org
Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen
in Japan. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …

[引用][C] Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan

M Namba, Y Kaneda, M Iida - Therapeutic advances in …, 2023 - pubmed.ncbi.nlm.nih.gov
Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing
regimen in Japan Stagnation or safety? Reassessment of the human papillomavirus …

[HTML][HTML] Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan

M Namba, Y Kaneda, M Iida - Therapeutic Advances in Vaccines …, 2023 - ncbi.nlm.nih.gov
TherapeuTic advances in vaccines and immunotherapy population across 47 countries
includes male vaccination within their routine immunization programs. 5 The HPV vaccine …